ESR1 and breast carcinoma: According to the German Institute for Quality and Efficiency in Healthcare (IQWiG) [5] to date there is no evidence neither of benefit nor harm of a biomarker-based strategy for the decision for or against chemotherapy in primary early stage estrogen receptor positive breast cancer.